PURPOSE To evaluate the visual and anatomical outcomes for neovascular age-related macular degeneration with submacular hemorrhage after intravitreal injections of tenecteplase (TNK), anti-vascular endothelial growth factor (VEGF) and expansile gas. METHODS This study was a retrospective clinical case series following 25 eyes of 25 patients. All patients received a triple injection using 0.05...

© T O U C H B R I E F I N G S 2 0 1 2 Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy, introduced in 2004, has evolved over the last decade to revolutionize the treatment of patients suffering from subretinal choroidal neovascularization (CNV). Anti-VEGF agents, which are readily available today, are much better, more potent, and longer acting in comparison with prev...

The majority of severe visual loss in the United States results from complications associated with retinal neovascularization in patients with ischemic ocular diseases such as diabetic retinopathy, retinal vein occlusion, and retinopathy of prematurity. Intraocular expression of the angiogenic protein vascular endothelial growth factor (VEGF) is closely correlated with neovascularization in the...

AIM: To evaluate and compare the anatomical functional outcomes negative effects of three anti-vascular endothelial growth factor (VEGF) drugs in treatment macular edema (ME) due to retinal vein occlusion (RVO) based on evidence pooled from current clinical trials observational studies. METHODS: A systematic literature search was conducted nine online databases inception until April 30, 2022. T...

Diabetic macular edema (DME) is the leading cause of sight-threatening complication in diabetic patients, and several treatment modalities have been developed and evaluated to treat this pathology. Intravitreal agents, such as anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids, have become more popular in recent years and are widely used for treating DME. Sustained release ...

Intravitreal injection of ranibizumab, an antivascular endothelial growth factor (VEGF) drug, is currently the primary treatment for wet age-related macular degeneration (AMD) in the UK. Use of ranibizumab for the treatment of isolated pigment epithelial detachments (PEDs) without the presence of an occult choroidal neovascular membrane has not been studied in a randomized controlled fashion an...

R etinal vein occlusion (RVO) causes vision loss mostly because of the development of intraretinal leakage that leads to macular edema. The treatment of cystoid macular edema (CME) secondary to RVO has evolved considerably during the past decade. Anti-VEGF agents have become the standard of care for CME secondary to both branch (BRVO) and central retinal vein occlusion (CRVO). Because the under...